Pay in 4 interest-free payments of $7.01 Learn more
Ships within 48 hours · Estimated delivery Aug 11 - Aug 16
call 999 for severe or rapidly worsening symptoms
About Fractyl Health Fractyl Health is a clinical-stage metabolic therapeutics company advancing two differentiated candidates designed to target the root causes of obesity and T2D: Revita, a procedural therapy in pivotal development for post-GLP-1 weight maintenance, and Rejuva, an AAV-based gene therapy platform with its lead candidate RJVA-001 entering first-in-human clinical studies
(2021) Cell Rep 36 : 109374-109374 PubMed: 34260945 Search on PubMed DOI: Primary Citation Related Structures: 7KI0, 7KI1 PubMed Abstract: The glucagon-like peptide-1 receptor (GLP-1R) regulates insulin secretion, carbohydrate metabolism, and appetite and is an important target for treatment of type 2 diabetes and obesity
We prioritize data reliability, controlled conditions, and the advancement of best practices in peptide reconstitution and compound stability, supporting precise and reproducible research outcomes
US$ 24.43
US$ 22.00
US$ 28.23
US$ 22.66
US$ 22.06
